

paragraph in its place.

-- Thus bases 14760 to 14930 are essential for PSME function, but sequences extending from 14760 to 15091, provide for much stronger enhancer activity. The sequence of the region is shown in Figure 11 (SEQ ID NO.1).

IN THE CLAIMS

Please amend Claim 9, 10 and 17, as follow.

9. A recombinant polynucleotide according to claim 7 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 14930 as shown in Figure 11 (SEQ ID NO.1) or a sequence which hybridizes thereto under high stringency.

10. A recombinant polynucleotide according to claim 7 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 15091 as shown in Figure 11 (SEQ ID NO.1) or a sequence which hybridizes thereto under high stringency.

17. A recombinant expression cassette according to claim 15 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 14930 as shown in Figure 11 (SEQ ID NO.1) or a sequence which hybridizes thereto under high stringency.

18. A recombinant expression cassette according to claim 15 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 15091 as shown in Figure 11 (SEQ ID NO.1) or a sequence which hybridizes thereto under high stringency.

26. An isolated nucleic acid molecule, the nucleic acid molecule having enhancer activity and comprising

- (a) a sequence comprising nucleotides 14760 to 14930 as shown in Figure 11 (SEQ ID NO.1), or
- (b) a nucleic acid sequence which hybridizes under high stringency to the sequence defined in paragraph (a).

27. An isolated nucleic acid molecule, the nucleic acid molecule having enhancer activity and comprising

- (a) a sequence comprising nucleotides 14760 to 15091 as shown in Figure 11 (SEQ ID NO.1), or
- (b) a nucleic acid sequence which hybridizes under high stringency to the sequence defined in paragraph (a).

35. A method according to claim 33 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 14930 as shown in Figure 11 (SEQ ID NO.1) or a sequence which hybridizes thereto under high stringency.

36. A method according to claim 33 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 15091 as shown in Figure 11 (SEQ ID NO.1) or a sequence which hybridizes thereto under high stringency.

45. A method according to claim 43 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 14930 as shown in Figure 11 (SEQ ID NO.1) or a sequence which hybridizes thereto under high stringency.

46. A method according to claim 43 in which the enhancer element comprises a sequence comprising nucleotides 14760 to 15091 as shown in Figure 11 (SEQ ID NO.1) or a sequence which hybridizes thereto under high stringency.

IN THE DRAWINGS

Please replace Figure 11 with the attached amended Figure 11 in its place.

IN THE SEQUENCE LISTING

Please replace the Sequence Listing as originally filed with the attached substitute Sequence Listing in its place.

REMARKS

The specification is corrected and a substitute Sequence Listing and Figure 11 are herein submitted to properly designate Figure 11 as SEQ ID NO.1 in the specification and in Figure 11.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The changes to the specification are underlined. The attached page is captioned "Version With Markings To Show Changes Made."